AzTrials
AzTrials

SchizophreniaNCT05268809

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

A study testing Ketogenic diet in people with Schizophrenia and Bipolar Disorder, run by Northern California Institute of Research and Education at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Wide ranging cognitive deficits are major drivers of functional decline and poor outcomes in people with schizophrenia (SZ) and bipolar disorder (BD). Medications do not target pathophysiological mechanisms thought to underlie these deficits. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Schizophrenia, Bipolar Disorder
What is being tested?
Ketogenic diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
71 participants
Where
1 siteUnited States
Study dates
21 Apr 2022to 31 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female ages 18-65 years old
  • Able to attend 2 in-person visits at the San Francisco VA Medical Center
  • SCID-5 Schizophrenia or schizoaffective disorder stable on 2nd generation anti-psychotic (SZ) or bipolar disorder (BD)
  • Not currently on KETO diet
  • Willing to adhere to 4 wk. KETO diet or 4 wk. non-KETO diet per random assignment
  • Speak, read, comprehend English
  • Access to internet
  • Willing and able to heat up KETO meals

Who cannot join

  • Current Cancer diagnosis
  • Other SCID-5 Axis 1 disorder
  • Pregnancy, breastfeeding, or planned pregnancy
  • Current diagnosis of type 1 Diabetes Mellitus
  • Glucose-lowering drugs (other than metformin) or weight loss pills
  • History of gastric bypass surgery or any weight loss surgery
  • >10% weight fluctuation in past 2 years

Trial locations and contacts

1 site in 1 country.

United States1 site
  • San Francisco VA Medical Center

    San Francisco, California, 94121

Other trials in United States

About this study

Wide ranging cognitive deficits are major drivers of functional decline and poor outcomes in people with schizophrenia (SZ) and bipolar disorder (BD). Medications do not target pathophysiological mechanisms thought to underlie these deficits. In the search for interventions targeting underlying cognitive impairment in SZ and BD, we look comprehensively beyond just the brain and to the potential role of dysfunctional systemic metabolism.

Disrupted insulin and glucose metabolism are seen in medication-naïve first-episode SZ, suggesting that SZ itself, and not just the medications used to treat it, is associated with risk of Type 2 diabetes, cardiovascular morbidity and mortality, and more generally, accelerated aging. Even young people with SZ have increased risk of metabolic disease and cognitive deficits. Sadly, their life span is shortened by 15-20 years. BD is associated with similar but less severe disruptions in glucose and insulin metabolism and life expectancy.

Read more

Although the human brain is 2% of the body's volume, it consumes over 20% of its energy, and accordingly, the brain is particularly vulnerable to the dysregulation of glucose metabolism seen in SZ and BD. While glucose is considered to be the brain's default fuel, ketones provide 27% more free energy and are a major source of energy for the brain. Ketones prevent or improve various age-associated diseases, and a ketogenic diet (70% fat, 20% protein, 10% carbohydrates) has been posited as an anti-aging and dementia antidote.

The premise of the work is based on recent evidence that ketogenic diets improve dynamic neural network instability, related to cognitive deficits, aging, and Type 2 diabetes (Mujica-Parodi et al., Proc Natl Acad Sci U S A. 2020;117(11):6170-7.). The rigor of the work rests on findings of (1) poor cerebral glucose homeostasis in SZ and BD, (2) neural network instability in SZ and BD, and (3) direct effects of ketosis on network instability. Unknown is whether ketogenic diets can improve network instability in people with SZ and BD.

Read the detailed description

The diagnosis of schizophrenia (SZ) and bipolar disorder (BPD) as traditionally been based on "positive symptoms," such as delusions and hallucinations, and "negative symptoms," such as anhedonia and amotivation. Although not part of the diagnostic criteria, wide ranging cognitive deficits are common, and they are major drivers of functional decline, as well as poor social and occupational outcomes experienced as illness chronicity sets in. While antipsychotic medications treat positive symptoms, they do not improve cognitive deficits, nor do they target pathophysiological mechanisms thought to underlie these deficits. Accordingly, in the search for interventions targeting brain dysfunction underlying cognitive impairment in SZ, the investigators will look comprehensively beyond the brain to the potential role of dysfunctional systemic metabolism, given that obesity, insulin resistance, and associated systemic inflammation are co-morbidities. Modern anti-psychotic medications disrupt metabolic homeostasis, which may contribute to the brain dysconnectivity thought to underlie cognitive deficits. However, both SZ and BPD have been associated with disrupted insulin and glucose metabolism, reported appearing well before the advent of antipsychotic treatment, and consistent with a recent meta-analysis indicating these metabolic disturbances. In fact, insulin resistance and both SZ and BPD have been genetically linked. Thus, SZ and BPD themselves are associated with metabolic disease, while the anti-psychotic medications acutely induce insulin resistance, independent of food intake and weight gain, compounding the associated metabolic susceptibilities. The cause-and-consequence relationship of these disorders and insulin resistance is unknown, and whether re-establishing metabolic homeostasis improves the underlying neural substrates of cognition is also unknown.

The brain is an obligate "glucovore" and is particularly vulnerable to changes in glucose metabolism. Robust energy demands of the brain cannot be met by lipid transformation, and during times of glucose deprivation, they must be satisfied by ketone bodies. Disrupted central glucose metabolism, as observed in SZ and BPD patients, modulates peripheral metabolism by re-allocation of nutrients towards a brain-centric focus to maintain critical central functions. Low-carbohydrate high fat, or ketogenic, diets are an emerging therapy for insulin resistance, Type 2 diabetes, and associated co-morbidities. Increased ketones prevent or improve the symptoms of various age-associated diseases, reduce inflammation and the production of reactive oxygen species, and upregulate mitochondria in the brain. In addition, ketogenic diets have shown promise, but without the needed controls.

The premise of this proposal is based on a recent paper showing a ketogenic diet reduced 7T resting state fMRI neural network dynamic instability, a measure of how long a network of independent nodes maintains a stable connection. Instability is related to cognitive deficits, aging, and Type 2 diabetes in neurotypical adults. The investigator's fMRI data show similar network dynamic instability in SZ and BPD, adding to a larger literature showing static brain network dysconnectivity underlying neurocognitive deficits. Unknown is whether network instability can be rescued with a ketogenic diet, and whether improvements are mediated by ketogenic diet-induced increases in available ketone bodies as brain fuel, and/or with reductions in systemic inflammation and indices of metabolic syndrome.

The rigor of the proposed work rests on findings of (a) poor glucose homeostasis in SZ and BPD, (b) neural network instability in SZ and BPD, and (c) direct effects of ketosis on network instability in neurotypical adults. Unknown is how ketogenic diets might improve network instability in overweight/obese SZ and BPD with risk of insulin resistance. The investigators propose a mechanistic, prospective, pilot clinical study comparing 4-weeks of ketogenic diet (KETO) vs. diet as usual (DAU) on neural network instability in SZ and BPD. They will randomize 70 SZ and BPD (40-65 years old, balanced for sex) to KETO (n=35) or DAU (n=35). KETO meals will be delivered to participants by Metabolic Meals. Metabolic, inflammatory, and 7T MRI data will be acquired before and after the 4-week diet.

Aim 1: Assess changes in network instability with KETO and DAU in SZ and BD over the 4-week period. Hypothesis 1: KETO, relative to DAU, will improve network stability.

Aim 2: Establish metabolic and inflammatory indices as correlates of change in network instability with the KETO diet. Hypothesis 2: Improvements in network stability will be correlated with increased circulating ketone levels, and improved insulin sensitivity, reduced visceral fat, weight loss, and reduced systemic inflammation.

Aim 3: Assess neuropsychological function at baseline to determine whether it is correlated with baseline network instability in SZ and BD, similar to what has been reported in neurotypical adults. Hypothesis 3: Cognitive deficits will be related to network instability in SZ and BD at baseline. The over-arching hypothesis is: Disrupted metabolic homeostasis contributes to neural network instability in SZ and BD and that induction of ketosis restores it.

Being tested
Ketogenic diet
Keywords
ketogenic diet, metabolic syndrome, fMRI, functional connectivity
Medical subject headings
Schizophrenia, Bipolar Disorder, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ketogenic dietOther

    The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.

Study groups in NCT05268809
Study groupRoleWhat they receive
Ketogenic DietExperimentalThe ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
Receives: Other: Ketogenic diet
Diet as usualNo interventionThe Diet As Usual (DAU) participants will be asked to maintain their current dietary habits and will be discouraged from starting new diets during the 4-week study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in network stabilization after 4 weeks

    Will measure dynamic connectivity by assessing how long a network of independent nodes, within and between brain regions, maintains a stable connection. Instability or dynamic connectivity quantifies stochastic processes or other potential heterogeneity in connectivity over time at baseline and at 4 weeks (post-treatment).

    Measured: Baseline (0 weeks) and posttreatment (4 weeks)

  2. Change in body composition after 4 weeks

    Body composition will be determined by calculating the waist-hip ratio.

    Measured: Baseline (0 weeks) and posttreatment (4 weeks)

  3. Change in systemic inflammation after 4 weeks

    Systemic inflammation will be assayed by plasma C-Reactive Protein levels (VA Clinical Lab).

    Measured: Baseline (0 weeks) and posttreatment (4 weeks)

  4. Change in insulin resistance after 4 weeks

    Insulin resistance will be indirectly determined from fasting glucose and insulin levels using the homeostasis model assessment of insulin resistance (HOMA-IR). Plasma glucose and insulin levels will be determined by the VA Clinical Lab.

    Measured: Baseline (0 weeks) and posttreatment (4 weeks)

  5. Cognition Battery

    Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). This will enable the direct assessment of the relationship between network stability at baseline and cognition using the MATRICS battery to determine if the known relationship with general cognition in neuro-typical adults is also seen in SZ and BD.

    Measured: Baseline (0 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2022
  2. Study start21 Apr 2022
  3. Primary completion1 Aug 2025
  4. Study completion31 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
We will randomize 70 overweight/obese SZ and BD participants to receive either a ketogenic or Diet as Usual.
Masking
None (open label)
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05268809
Sponsor's protocol ID
613338789
Status last verified
Mar 2025
First submitted
6 Jan 2022
Last updated
12 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Ketogenic diet in people with Schizophrenia and Bipolar Disorder, run by Northern California Institute of Research and Education at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in network stabilization after 4 weeks (time frame: Baseline (0 weeks) and posttreatment (4 weeks)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT05268809 | AzTrials